Flannery E J
Hastings Cent Rep. 1986 Feb;16(1):17-23.
In applying statutory safeguards, the FDA must not regulate investigational new products so stringently that a life-saving therapy is unavailable. But the agency must also protect dying patients from exploitation by unscrupulous or overzealous researchers. The balance between individual choice and public protection has been questioned in cases involving experimental AIDS drugs and an artificial heart.
在应用法定保障措施时，美国食品药品监督管理局（FDA）对研究性新药的监管不能过于严格，以至于让一种救命疗法无法获取。但该机构也必须保护濒死患者免受无良或狂热研究人员的剥削。在涉及实验性艾滋病药物和人工心脏的案例中，个人选择与公共保护之间的平衡受到了质疑。
